In a real‐world study evaluating the effectiveness of combination therapy with an EGFR‐TKI plus bevacizumab versus EGFR‐TKI monotherapy for patients with EGFR‐mutated advanced NSCLC, combination therapy showed significantly longer PFS (median PFS: 17.0 vs. 11.0 months; HR [95%CI]: 0.48 [0.30–0.77], p = 0.002).30 This evidence concerns the gene EGFR and non-small cell lung carcinoma.